# Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2026-operating-results-and-provides-business-update
Ticker: SPRO
Company: Spero Therapeutics
Source: Spero Therapeutics
Published: 2026-05-13 16:05 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul type="disc"><li style="margin-bottom:6pt;"><em>New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at 

## Article Body
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026

Spero maintains its cash runway guidance into 2028

CAMBRIDGE, Mass., May...
## Recent Company News
- 2026-07-14 11:02 EST — [Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-financing-bac-d8d87fa7) — Source: Spero Therapeutics
- 2026-05-13 16:05 EST — [Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2026-operating-results-and-provides-business-update) — Source: Spero Therapeutics
- 2026-05-05 16:05 EST — [Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026](https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026) — Source: Spero Therapeutics
- 2026-03-26 16:05 EST — [Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2025-operating-results-and-provides-a-business-update) — Source: Spero Therapeutics
- 2026-03-18 16:05 EST — [Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026](https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-march-26-2026) — Source: Spero Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-na&#239;ve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)